Showing results (1511-1520 of 1,729) with videos related to

Sort By:
Pageof 173
Breast Cancer Research and Treatment|July 6, 2012
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerMartin Schuler, Ahmad Awada, Philipp Harter, et al.
Cadernos De Saude Publica|May 21, 2025
[Cluster predictors of trajectories of leisure-time physical activity intensity in men and women from ELSA-Brasil]André Luis Messias Dos Santos Duque, Daniela Polessa Paula, Francisco José Gondim Pitanga, et al.
Breast Cancer Research and Treatment|November 1, 2016
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN studyNadia Harbeck, Steffen Saupe, Elke Jäger, et al.
Current Biology : CB|May 5, 2023
An LRR receptor kinase controls ABC transporter substrate preferences during plant growth-defense decisionsBibek Aryal, Jian Xia, Zehan Hu, et al.
Acta Neuropathologica|March 27, 2023
Ganglioglioma with adverse clinical outcome and atypical histopathological features were defined by alterations in PTPN11/KRAS/NF1 and other RAS-/MAP-Kinase pathway genesLucas Hoffmann, Roland Coras, Katja Kobow, et al.
Journal of Neuro-Oncology|April 17, 2024
Improved outcomes for triple negative breast cancer brain metastases patients after stereotactic radiosurgery and new systemic approachesElad Mashiach, Juan Diego Alzate, Fernando De Nigris Vasconcellos, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaboratorsDominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
The Lancet. Oncology|July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialEric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 26, 2017
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factorsJ McGee, M Bookman, P Harter, et al.
Cadernos De Saude Publica|November 16, 2023
Impact of socioeconomic factors on lifestyle changes among employees of public higher education institutions in ELSA-Brasil during COVID-19 pandemicMaria Del Carmen Bisi Molina, Carla Moronari de Oliveira Aprelini, Adriana Lúcia Meireles, et al.
Pageof 173